It has been shown that treatment with MAPKi leads to increased numbers of TAM in melanoma lesions, and that tumor necrosis factor (TNF) released by TAMs induces melanoma resistance to MAPKi, blocking apoptosis mediated by inhibition of BRAF signaling [9–11]. This evidence concerns the gene TNF and melanoma.